references
- Maia H Jr, Casoy J, Athayde C, et al. The effect of a continuous regimen of drospirenone 3 mg/ethinylestradiol 30 μg on Cox-2 and Ki-67 expression in the endometrium. Eur J Contracept Reprod Health Care 2010;15:35–40.
- Andrija Stampar Institute of Public Health. Izvanbolnička potrošnja lijekova u gradu Zagrebu u 2008. godini [Outpatient drug consumption in the city of Zagreb in 2008]. Zagreb 2009.
- http://www.almp.hr/?ln = hr&w = publikacije&d =nuspojave_2009 (Accessed 30 August 2010).
- Shulman LP, Goldzieher JW. The truth about oral contraceptives and venous thromboembolism. J Reprod Med 2003;48(11 Suppl):930–8.
- Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323(7305):131, doi: 10.1136/bmj.323.7305.131
- http://www.stampar.hr/Default.aspx (Accessed 30 August 2010).
- van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921 doi: 10.1136/bmj.b2921
- Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890 doi: 10.1136/bmj.b2890
- Martínez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care 2007;12:97–106.